Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients

• Status: Completed
• Trial end date: 2021-02-24
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy and safety of T4032 versus Lumigan.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laboratoires Thea
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Informed consent signed and dated.

• Both eyes with diagnosed open-angle glaucoma or ocular hypertension

Exclusion Criteria:

• History of trauma, infection, clinically significant inflammation within the 3 previous months.

• Uncontrolled diabetic patient.

• Pregnancy or breast feeding.